BioEscalator Bulletin #8 beautifully captures how we wanted the facility to work when it was established in 2018 to nurture companies through the early stages of medical science research translation.

Over the last three months, we’ve seen new companies such as Re-AIM and SiGenex become tenants, expansion and fundraising from Granza Bio, while MediMabBio and Bioarchitech have graduated to new sites for further growth towards human health impact.
 

Our Management Board has continued to show its flair for translation, with Duncan Richards discussing experimental medicine in drug discovery and development in a BioEscalator seminar and Angela Russell’s involvement in another start-up.

In addition, Chas Bountra and his team are involved in the new collaboration between the University of Oxford, Oxford University Innovation and Apollo Therapeutics to accelerate drug discovery and development from Oxford’s world-class research.
 

Enjoy the update.
 

Matthew Wood, Professor of Neuroscience, Chair of BioEscalator Management Board & entrepreneur